Quintiles Ranks First in Pan-European Clinical Investigator Study

World's leading pharma services company rated highest in overall satisfaction

RESEARCH TRIANGLE PARK, N.C., April 10 /PRNewswire/ -- Quintiles
Transnational Corp. today announced that an independently conducted study of
clinical investigator sites across Europe placed Quintiles first in overall
satisfaction. Quintiles also rated first in several other indicators of a
clinical investigator's commitment to work with the world's leading
pharmaceutical services provider.
Eighty-four percent of sites indicated that they were satisfied or
extremely satisfied with their relationship with Quintiles.
The study, blinded and conducted by a third party, asked more than 300
European clinical investigators in 18 countries to rate their relationships
and experience with Clinical Research Organizations (CROs). Investigators
recruit patients and collect data for CROs and their pharmaceutical and
biotechnology sponsors in studies that test drugs for safety and efficacy.
Quintiles and eight other CROs were rated on 15 attributes by the investigator
sites, including overall satisfaction, relationship building and allocation of
resources for projects, including staff time.
"It is especially pleasing to see these results from all of our efforts to
build strong relationships with investigators," said Lindy Jones, Vice
President, Clinical Operations, Western Europe and Africa. "Because of our
hard work, it is clear the sites are willing to devote more of their resources
to projects they conduct with Quintiles than other CROs."
Clinical sites were asked to assign a percentage of resources -- such as
time spent on patient recruitment -- that they had used on clinical studies
with each CRO. Quintiles was allocated 38% of resources by the sites, with
the nearest competitor being assigned only 13%, according to the survey. As
for expected allocation of resources in the future, sites plan to continue
giving additional resources to Quintiles projects at about a 3:1 ratio over
other CROs.
"Allocation of resource is an important measure because it tells us where
sites are more willing to put their limited time and effort," said Jones.
"These results show that sites feel they get more return on their investment
by working with Quintiles."
The relationship measurement was based on the question, "Which provider
works hardest to develop a relationship with you/your site?" Quintiles was
named by 49% of respondents. The closest competitor was named by only 10%.
Janos Filakovsky, Vice President and Managing Director, Eastern Region and
Middle East, said, "Our continuing efforts to build strong relationships
ultimately lead to more efficient use of time and resources, and that makes
our customers happy. The end goal is more accurate feasibility, faster
recruitment and safer patient management in clinical trials."
A third-party research company interviewed 308 investigators across Europe
from January to February 2008. Investigators rated only those CROs with whom
they had worked in the last 18 months. Respondents had an average of 13 years
of experience in conducting clinical research, and sites had conducted an
average of 11 studies over the last 18 months. For source data, please refer
to www.quintiles.com/results .
About Quintiles
Quintiles Transnational Corp. is powering the next generation of
healthcare by providing a broad range of professional services in drug
development, financial partnering and commercialization for the
pharmaceutical, biotechnology and healthcare industries. With more than 20,000
employees and offices in more than 50 countries, it is focused on providing
customer-centric solutions that are the gold standard of the industry. For
more information, please visit the company's Web site at www.quintiles.com.
SOURCE Quintiles Transnational Corp.

Dick Jones, Media Relations, +1-919-998-2091, media.info@quintiles.com, or
Greg Connors, Investor Relations, +1-919-998-2000, invest@quintiles.com